News
DCPH
14.18
-3.01%
-0.44
Weekly Report: what happened at DCPH last week (0415-0419)?
Weekly Report · 3d ago
Commit To Purchase Deciphera Pharmaceuticals At $7.50, Earn 15.7% Annualized Using Options
NASDAQ · 04/16 16:47
Weekly Report: what happened at DCPH last week (0408-0412)?
Weekly Report · 04/15 09:25
Deciphera Pharmaceuticals Insiders Sell US$1.6m Of Stock, Possibly Signalling Caution
Deciphera Pharmaceuticals, Inc. Insiders sold US$471k worth of shares over the last year. The biggest sale was by the President of the company, Steven Hoerter, for US$15.37 per share. In the last 12 months, Deciphera pharmaceuticals insiders have sold more shares than they bought. The company has a high level of insider ownership, but it's not a good sign for shareholders. You can see the insider transactions at Decipher a Pharmaceuticals over the past year.
Simply Wall St · 04/09 10:03
Deciphera Pharmaceuticals to Present at the Stifel 2024 Virtual Targeted Oncology Forum
Deciphera Pharmaceuticals, Inc. Will participate in a fireside chat at the Stifel 2024 Virtual Targeted Oncology Forum on April 16, 2024 at 11:30am ET. The company is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer.
Barchart · 04/09 06:00
Analysts Have Conflicting Sentiments on These Healthcare Companies: Deciphera Pharmaceuticals (DCPH) and Shockwave Medical (SWAV)
TipRanks · 04/08 12:40
Weekly Report: what happened at DCPH last week (0401-0405)?
Weekly Report · 04/08 09:27
Weekly Report: what happened at DCPH last week (0325-0329)?
Weekly Report · 04/01 09:26
Weekly Report: what happened at DCPH last week (0318-0322)?
Weekly Report · 03/25 09:27
Deciphera Pharmaceuticals Is Maintained at Neutral by JP Morgan
Dow Jones · 03/21 17:58
U.S. RESEARCH ROUNDUP-Dick's Sporting Goods, Nvidia, PVH
Wall Street analysts revise their ratings and price targets on several U.S.-listed companies. Dick's Sporting Goods, Nvidia and PVH are among the companies. Hilton Worldwide Holdings and Cisco also raise their targets for the day. Some analysts raised their target prices for the companies on Wednesday.
Reuters · 03/20 07:14
Weekly Report: what happened at DCPH last week (0311-0315)?
Weekly Report · 03/18 09:27
We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth
Deciphera Pharmaceuticals (NASDAQ:DCPH) has a negative free cash flow of US$147m. The company's cash burn is the rate at which it spends cash to fund its growth. Deciphera pharmaceuticals has a good cash runway of 2.1 years. It has US$306m in cash and is expected to break even in about 3 years. The biotech company is in a good position to raise more cash to fuel its growth in the future.
Simply Wall St · 03/13 10:20
Weekly Report: what happened at DCPH last week (0304-0308)?
Weekly Report · 03/11 09:26
Big Pharma patent cliffs seen fueling oncology M&A this year
Big Pharma patent cliffs seen fueling oncology M&A this year. Around $182B in revenue is at risk over the next four years due to patent expirations. Cantor Fitzgerald sees between five and 17 acquisition deals for oncologists in 2014. The global market for cancer drugs is expected to grow from $180B in 2022 to $323B in 2028.
Seeking Alpha · 03/10 17:08
Weekly Report: what happened at DCPH last week (0226-0301)?
Weekly Report · 03/04 09:27
Wall Street Analysts Think Deciphera Pharmaceuticals, Inc. (DCPH) Could Surge 48.49%: Read This Before Placing a Bet
NASDAQ · 02/28 14:55
Look Under The Hood: XBI Has 44% Upside
NASDAQ · 02/26 11:58
Weekly Report: what happened at DCPH last week (0219-0223)?
Weekly Report · 02/26 09:29
Barclays Keeps Their Sell Rating on Deciphera Pharmaceuticals (DCPH)
TipRanks · 02/21 11:51
More
Webull provides a variety of real-time DCPH stock news. You can receive the latest news about Deciphera Pharma through multiple platforms. This information may help you make smarter investment decisions.
About DCPH
Deciphera Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing new medicines to improve the lives of people with cancer. The Company is leveraging its switch-control kinase inhibitor platform in kinase biology to develop a portfolio of medicines. The Company's QINLOCK, is a switch-control kinase inhibitor, engineered using its drug discovery platform and developed for the treatment of fourth-line gastrointestinal stromal tumor (GIST). In addition to QINLOCK, it has developed a robust pipeline of drug candidates using its switch-control kinase inhibitor platform, including vimseltinib and DCC-3116. Vimseltinib is an investigational, orally administered, potent, and highly-selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) kinase for the potential treatment of tenosynovial giant cell tumor (TGCT). DCC-3116 is a Phase 1/2 inhibitor of ULK kinases being developed to inhibit autophagy.